Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2457072 | 0.84 | FAAH (0.64) | FAAHALDH1A1MAPK1LMNAHTT | |
| SCHEMBL12220835 | 0.83 | FAAH (0.51) | FAAHALDH1A1MAPK1LMNAHTT | |
| SCHEMBL2458542 | 0.82 | FAAH (0.51) | FAAHALDH1A1MAPK1LMNAHTT | |
| SCHEMBL3942954 | 0.81 | FAAH (0.75) | FAAHALDH1A1MAPK1LMNAHTT | |
| SCHEMBL2458221 | 0.81 | ALPL (0.51) | FAAHLMNAALPL | |
| SCHEMBL2456991 | 0.81 | FAAH (0.47) | FAAHMAPK1TNFEGFRERBB2 | |
| SCHEMBL7911636 | 0.81 | FAAH (0.49) | FAAHALDH1A1MAPK1LMNAHTT | |
| SCHEMBL2457391 | 0.80 | FAAH (0.50) | FAAHALDH1A1MAPK1LMNAHTT | |
| SCHEMBL2459587 | 0.80 | FAAH (0.49) | FAAHALDH1A1MAPK1LMNAHTT | |
| SCHEMBL7903064 | 0.80 | FAAH (0.48) | FAAHALDH1A1MAPK1ALPLKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | claimed |
| EP-2364316-A1 | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d¨pyrimidin-4-yl]-quinolin-3 -ylamine compounds useful as FAAH modulators and uses thereof | Renovis, Inc. (US) | 2011-09-14 | — | — | EP | claimed |
| WO-2010059610-A1 | 6, 7 -DIHYDRO- 5H- PYRROLO [3, 4-D] PYRIMIDIN-4-YL] -QUINOLIN-3 -YLAMINE COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| EP-2364316-A1 | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d¨pyrimidin-4-yl]-quinolin-3 -ylamine compounds useful as FAAH modulators and uses thereof | Renovis, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010059610-A1 | 6, 7 -DIHYDRO- 5H- PYRROLO [3, 4-D] PYRIMIDIN-4-YL] -QUINOLIN-3 -YLAMINE COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059610-A1 | 6, 7 -DIHYDRO- 5H- PYRROLO [3, 4-D] PYRIMIDIN-4-YL] -QUINOLIN-3 -YLAMINE COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | FAAH, FAAH2, CNR2 | FAAH 1/4885ALDH1A1 669/4885MAPK1 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.